US biotech ImmunityBio (Nasdaq: IBRX) has secured $75 million through a direct offering with a single institutional investor, ...

DelveInsight's Merkel Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment ...

It’s a biotech environment without many good choices. Even before President Donald Trump’s tariff announcement pushed stock ...

FDA removes safety program requirement for Idorsia's blood pressure drug Tryvio, Solu gets $41M Series A with Eli Lilly ...

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

We recently published a list of Tuesday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ...

ImmunityBio, Inc. (NASDAQ: IBRX) has announced the execution of a $75 million equity financing with a single institutional ...

In this article, we will discuss the 10 Stocks under $10 that will triple.

Scientist.com, the leading R&D procurement orchestration platform for the life sciences, today announced the launch of Clinical Labs Navigatortm, a groundbreaking new tool that redefines how clinical ...

ImmunityBio (IBRX) announced that it has executed financing to provide further working capital and support its ongoing business operations. The ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide ...

ImmunityBio, Inc.’s IBRX share price has dipped by 6.07%, which has investors questioning if this is right time to buy.